This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EU extends IMS Health, Cegedim review following remedies

By Christiaan Nelisse ( December 3, 2014, 10:37 GMT | Insight) -- IMS Health Holdings, a company that sells prescription data and consulting services to drugmakers, is seeking to overcome EU antitrust concerns by offering to revise the terms of its proposed buyout of two businesses owned by rival Cegedim. The proposed remedies, submitted yesterday, have pushed the European Commission’s decision deadline back by 10 working days, to Dec. 23 from Dec. 9.IMS Health Holdings, a company that sells prescription data and consulting services to drugmakers, is seeking to overcome EU antitrust concerns by offering to revise the terms of its proposed buyout of two businesses owned by rival Cegedim....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login